Zhao SP - Search Results

1

Prevalence and risk factors associated with hypertension in the Chinese Qiang population.

Huang XB, Chen F, Dai W, Song L, Tu J, Xu JB, Liu JX, Yi YJ, Liu Y, Chen Y, Wang TD, Zhao SP. Huang XB, et al. Among authors: zhao sp. Clin Exp Hypertens. 2018;40(5):427-433. doi: 10.1080/10641963.2017.1392553. Epub 2017 Nov 6. Clin Exp Hypertens. 2018. PMID: 29106313 Free article.

2

A prospective study of cognitive emotion regulation strategies and depressive symptoms in patients with essential hypertension.

Xiao J, Yao S, Zhu X, Abela JR, Chen X, Duan S, Zhao S. Xiao J, et al. Clin Exp Hypertens. 2011;33(1):63-8. doi: 10.3109/10641963.2010.531832. Epub 2010 Dec 19. Clin Exp Hypertens. 2011. PMID: 21166601 Free article.

3

No evidence to support high-intensity statin in Chinese patients with coronary heart disease.

Dai W, Huang XS, Zhao SP. Dai W, et al. Among authors: zhao sp. Int J Cardiol. 2016 Feb 1;204:57-8. doi: 10.1016/j.ijcard.2015.11.164. Epub 2015 Nov 23. Int J Cardiol. 2016. PMID: 26655539 No abstract available.

4

Prevalence, awareness, treatment, and control of hypertension among China's Sichuan Tibetan population: A cross-sectional study.

Huang X, Zhou Z, Liu J, Song W, Chen Y, Liu Y, Zhang M, Dai W, Yi Y, Zhao S. Huang X, et al. Clin Exp Hypertens. 2016;38(5):457-63. doi: 10.3109/10641963.2016.1163369. Epub 2016 Jun 30. Clin Exp Hypertens. 2016. PMID: 27359364 Free article.

5

Prevalence of diabetes and unrecognized diabetes in hypertensive patients aged 40 to 79 years in southwest China.

Huang XB, Tang WW, Liu Y, Hu R, Ouyang LY, Liu JX, Li XJ, Yi YJ, Wang TD, Zhao SP. Huang XB, et al. Among authors: zhao sp. PLoS One. 2017 Feb 13;12(2):e0170250. doi: 10.1371/journal.pone.0170250. eCollection 2017. PLoS One. 2017. PMID: 28192474 Free PMC article.

6

Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy.

Zhao W, Zheng XL, Jiang ZN, Liao XB, Zhao SP. Zhao W, et al. Among authors: zhao sp. Int J Cardiol. 2017 Dec 1;248:355-360. doi: 10.1016/j.ijcard.2017.06.105. Epub 2017 Jun 30. Int J Cardiol. 2017. PMID: 28689987

7

Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARα signaling pathway.

Zhao SP, Li R, Dai W, Yu BL, Chen LZ, Huang XS. Zhao SP, et al. PLoS One. 2017 Sep 21;12(9):e0184949. doi: 10.1371/journal.pone.0184949. eCollection 2017. PLoS One. 2017. PMID: 28934253 Free PMC article.

8

Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease.

Dai W, Long J, Cheng Y, Chen Y, Zhao S. Dai W, et al. Sci Rep. 2018 May 16;8(1):7726. doi: 10.1038/s41598-018-25835-5. Sci Rep. 2018. PMID: 29769559 Free PMC article.

9

Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study.

Dai W, Zhang Z, Zhao S. Dai W, et al. Lipids Health Dis. 2018 Dec 3;17(1):273. doi: 10.1186/s12944-018-0923-1. Lipids Health Dis. 2018. PMID: 30509306 Free PMC article.

10

miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.

Long JK, Dai W, Zheng YW, Zhao SP. Long JK, et al. Among authors: zhao sp. Mol Med. 2019 Jun 13;25(1):26. doi: 10.1186/s10020-019-0085-2. Mol Med. 2019. PMID: 31195981 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

414 results

Search Page

Filters